Appeals Court Orders FDA To Stay ANDA Approval For Neurontin Generic Capsules

Law360, New York (July 28, 2004, 12:00 AM EDT) -- A federal appeals court has ordered the U.S. Food and Drug Administration to stay final approval of the Alpharma’s generic version of Pfizer's epilepsy treatment Neurontin pending an appeal.

The U.S. Court of Appeals for the District of Columbia ordered the FDA to stay final approval for Alpharma's Abbreviated New Drug Application (ANDA) for gabapentin capsules be stayed pending a resolution of the appeal of litigation brought by Canadian generics maker Apotex, Inc.

Apotex has challenged Alpharma's entitlement to 180-day marketing exclusivity for these capsules. The...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.